|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 78.61 USD | +0.27% |
|
+0.62% | +4.02% |
| 07-07 | RBC Capital Adjusts PTC Therapeutics Price Target to $85 From $82, Maintains Sector Perform Rating | MT |
| 06-28 | PTC Therapeutics, Inc.(NasdaqGS:PTCT) added to Russell 2000 Value-Defensive Index | CI |
Company Valuation: PTC Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 2,816 | 2,786 | 2,080 | 3,481 | 6,099 | 6,503 | - | - |
| Change | - | -1.06% | -25.35% | 67.4% | 75.18% | 6.63% | - | - |
| Enterprise Value (EV) 1 | 2,474 | 2,947 | 1,487 | 2,627 | 4,440 | 4,642 | 4,554 | 3,777 |
| Change | - | 19.12% | -49.54% | 76.65% | 69% | 4.56% | -1.9% | -17.07% |
| P/E | -5.36x | -4.9x | -3.29x | -9.54x | 9.76x | 107x | 30.2x | 24.5x |
| PBR | 1,952x | -7.89x | -2.55x | -3.19x | -30.1x | -32.5x | 69.4x | 6.89x |
| PEG | - | -1.01x | -0.44x | 0.2x | -0x | -1.2x | 0x | 1x |
| Capitalization / Revenue | 5.23x | 3.99x | 2.22x | 4.32x | 3.52x | 5.5x | 4.84x | 4.09x |
| EV / Revenue | 4.59x | 4.22x | 1.59x | 3.26x | 2.57x | 3.93x | 3.39x | 2.38x |
| EV / EBITDA | -7.97x | -9.25x | -7.33x | -11.6x | 4.9x | 15.2x | 8.93x | 5.05x |
| EV / EBIT | -6.61x | -6.59x | -3.38x | -8.68x | 5.12x | 16.4x | 10.4x | 6.49x |
| EV / FCF | -8.85x | -7.58x | -7.96x | -23x | 6.32x | -41.1x | 55.5x | 23.6x |
| FCF Yield | -11.3% | -13.2% | -12.6% | -4.35% | 15.8% | -2.43% | 1.8% | 4.24% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -7.43 | -7.79 | -8.37 | -4.73 | 7.78 | 0.736 | 2.594 | 3.203 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 538.6 | 698.8 | 937.8 | 806.8 | 1,731 | 1,183 | 1,344 | 1,590 |
| EBITDA 1 | -310.3 | -318.6 | -202.9 | -226.9 | 905.8 | 305.8 | 510.1 | 748.4 |
| EBIT 1 | -374.4 | -447.4 | -439.5 | -302.6 | 866.9 | 283 | 435.9 | 581.8 |
| Net income 1 | -523.9 | -559 | -626.6 | -363.3 | 682.6 | 51.95 | 194.6 | 318 |
| Net Debt 1 | -341.9 | 161 | -592.5 | -854.3 | -1,659 | -1,861 | -1,949 | -2,727 |
| Reference price 2 | 39.83 | 38.17 | 27.56 | 45.14 | 75.96 | 78.40 | 78.40 | 78.40 |
| Nbr of stocks (in thousands) | 70,698 | 72,991 | 75,463 | 77,125 | 80,288 | 82,949 | - | - |
| Announcement Date | 2/22/22 | 2/21/23 | 2/29/24 | 2/27/25 | 2/19/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 113.5x | 3.93x | 15.18x | -.--% | 6.5B | |
| 34.57x | 12.36x | 25.86x | 0.58% | 1,037B | |
| 27.4x | 6.26x | 17.33x | 2.1% | 615B | |
| 33x | 7.49x | 15.4x | 2.71% | 448B | |
| 17.76x | 4.4x | 10.85x | 3.01% | 326B | |
| 21.11x | 5.63x | 13.79x | 2.84% | 293B | |
| 21.21x | 4.47x | 12.37x | 1.97% | 264B | |
| 14.09x | 5.24x | 10.8x | 3.55% | 216B | |
| 24.01x | 6.34x | 11.18x | 2.76% | 198B | |
| -46.95x | 5.62x | 31.09x | 2.53% | 162B | |
| Average | 25.97x | 6.18x | 16.39x | 2.21% | 356.39B | |
| Weighted average by Cap. | 24.12x | 7.75x | 18.20x | 2.01% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- PTCT Stock
- Valuation PTC Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
